Source:http://linkedlifedata.com/resource/pubmed/id/11598313
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2001-10-12
|
pubmed:abstractText |
As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer's disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer's disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chelating Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clioquinol,
http://linkedlifedata.com/resource/pubmed/chemical/Copper,
http://linkedlifedata.com/resource/pubmed/chemical/GAP-43 Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Zinc,
http://linkedlifedata.com/resource/pubmed/chemical/tau Proteins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1420-8008
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2001 S. Karger AG, Basel
|
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
408-14
|
pubmed:dateRevised |
2008-3-24
|
pubmed:meshHeading |
pubmed-meshheading:11598313-Aged,
pubmed-meshheading:11598313-Aged, 80 and over,
pubmed-meshheading:11598313-Alzheimer Disease,
pubmed-meshheading:11598313-Chelating Agents,
pubmed-meshheading:11598313-Chelation Therapy,
pubmed-meshheading:11598313-Clioquinol,
pubmed-meshheading:11598313-Copper,
pubmed-meshheading:11598313-Dose-Response Relationship, Drug,
pubmed-meshheading:11598313-Female,
pubmed-meshheading:11598313-GAP-43 Protein,
pubmed-meshheading:11598313-Humans,
pubmed-meshheading:11598313-Male,
pubmed-meshheading:11598313-Middle Aged,
pubmed-meshheading:11598313-Treatment Outcome,
pubmed-meshheading:11598313-Zinc,
pubmed-meshheading:11598313-tau Proteins
|
pubmed:articleTitle |
Treatment of Alzheimer's disease with clioquinol.
|
pubmed:affiliation |
Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital/Mölndal, SE-431 80 Mölndal, Sweden. bjorn.regland@vgregion.se
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|